Vir Biotechnology (VIR) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $27.00 from $23.00 | Jun 11, 2026 |
| Leerink Partners | Maintained | Outperform | $21.00 from $20.00 | Jun 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $15.00 | Mar 4, 2026 |
| Barclays | Maintained | Overweight | $30.00 from $26.00 | Feb 25, 2026 |
| Needham | Maintained | Buy | $18.00 from $14.00 | Feb 24, 2026 |
| Evercore ISI Group | Maintained | Outperform | $18.00 from $12.00 | Feb 24, 2026 |
| Morgan Stanley | Maintained | Overweight | $24.00 from $20.00 | Feb 24, 2026 |
| Needham | Maintained | Buy | $14.00 | Feb 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Dec 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Sep 15, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $12.00 | Sep 3, 2025 |
| B of A Securities | Upgraded | Neutral → Buy | $14.00 from $12.00 | Aug 27, 2025 |
| Raymond James | Initiated Coverage | Outperform | $12.00 | Jul 11, 2025 |
| Needham | Maintained | Buy | $14.00 | May 22, 2025 |
| Needham | Maintained | Buy | $14.00 from $19.00 | May 12, 2025 |
| Goldman Sachs | Maintained | Buy | $21.00 from $28.00 | Apr 17, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $110.00 | Feb 28, 2025 |
| Barclays | Maintained | Overweight | $31.00 from $26.00 | Feb 28, 2025 |
| Needham | Maintained | Buy | $19.00 | Feb 27, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $110.00 | Jan 31, 2025 |
Frequently asked questions
Is VIR a buy, sell, or hold?
Analysts covering Vir Biotechnology currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on VIR?
On Jun 11, 2026, Morgan Stanley maintained Vir Biotechnology at Overweight with a price target of $27.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.